LYSOSOMAL STORAGE DISEASES THERAPEUTICS MARKET ANALYSIS

Lysosomal Storage Diseases Therapeutics MarketSize and Trends

The global lysosomal storage diseases therapeutics market is estimated to be valued at US$ 9.87 Billion in 2023 and is expected to exhibit a CAGR of 8.4 % during the forecast period (2023-2030).

Figure 1. Global Lysosomal Storage Diseases Therapeutics Market Share (%), by Product Type, 2023

Market Trends:

Increasing prevalence of lysosomal storage diseases, increasing products launch can drive the growth of global lysosomal storage diseases (LSD) therapeutics market. Lysosomal storage diseases are believed to have an estimated frequency of about one in every 5,000 live births. For instance, according to an article published by Molecular Genetics and Metabolism in July 2021, study was conducted to check prevalence of patients with lysosomal storage disorders and peroxisomal disorders by conducting a nationwide survey in Japan. A total of 13,304 hospitals with more than 20 hospitalized beds in Japan were surveyed for their experience in treating patients with LSD. The number of patients was estimated by calculating the rate/frequency of overlap. The estimated number of patients was 1658 for Fabry disease, 72 for mucopolysaccharidosis I, 275 for mucopolysaccharidosis II, 211 for Gaucher disease, 124 for Pompe disease, 83 for metachromatic leukodystrophy, 57 for Niemann-Pick type C, and 262 for adrenoleukodystrophy. In addition the birth prevalence was calculated using the estimated number of patients and birth year data for each disease, and was 1.25 for Fabry disease, 0.09 for mucopolysaccharidosis I, 0.38 for mucopolysaccharidosis II, 0.19 for Gaucher disease, 0.14 for Pompe disease, 0.16 for metachromatic leukodystrophy, 0.16 for Niemann-Pick type C, and 0.20 for adrenoleukodystrophy.

Figure 2. Global Lysosomal Storage Diseases Therapeutics Market Value (US$ Billion), by Region, 2023